Elesclomol (STA-4783)

製品コードS1052

Elesclomol (STA-4783)化学構造

分子量(MW):400.5

Elesclomol (STA-4783) is a novel potent oxidative stress inducer that elicits pro-apoptosis events among tumor cells. Phase 3.

サイズ 価格(税別)  
JPY 31540.00
JPY 28220.00
JPY 53120.00
JPY 161020.00

カスタマーフィードバック(4)

  • Treatment with elesclomol inhibits cancer cell growth and induces apoptosis by increasing ROS levels. a. Cell growth of SMOV2, IGROV1, and OVCA432 ovarian cancer cells treated with elesclomol in the presence or absence of the antioxidant NAC for 72 h. Cell growth was measured using the WST-1 assay and quantified relative to DMSO treated controls.

    Oncotarget, 2016, 7(35):56933-56943. Elesclomol (STA-4783) purchased from Selleck.

    BMC Genomics 2014 15(1), 263. Elesclomol (STA-4783) purchased from Selleck.

  • Overexpression of GILZ favors oxidative cell death Dose-response of ROS production (HE staining) (A) or cell death (PI staining) (B) in indicated cells exposed toincreasing concentrations of elesclomol for 24 h (mean ± SD, n = 3, *p < 0.05). Alternatively, cells were treated with elesclomol for 24 h with or without pre-incubation with10 mM N-Acetyl Cysteine (NAC) for 12 h before HE staining (A) or PI staining (B) (mean ± SD, n = 3, *p < 0.05).

    Int J Biochem Cell Biol, 2017, 85:166-174. Elesclomol (STA-4783) purchased from Selleck.

    The proliferation of PC3 and LNCaP cells exposed to elesclomol at a range of concentrations for 48 h was assessed using MTT assay. Results are expressed as percentage of MTT absorbance of untreated cells at 0 h. p < .05 and p < .01 compared to untreated controls. Data are means ± SEM; n = 4.

    Int J Radiat Biol, 2017, 93(2):194-203. Elesclomol (STA-4783) purchased from Selleck.

製品安全説明書

HSP (e.g. HSP90)阻害剤の選択性比較

生物活性

製品説明 Elesclomol (STA-4783) is a novel potent oxidative stress inducer that elicits pro-apoptosis events among tumor cells. Phase 3.
ターゲット
HSP70 [1]
(Cell-free assay)
体外試験

Elesclomol significantly induces the expression of heat shock stress response genes and metallothionein genes, a signature transcription profile indicative of oxidative stress in Hs294T cells. Elesclomol (100 nM) rapidly induces Hsp70 RNA levels with a 4.8-fold increase at 1 hour and a 160-fold increase at 6 hours in Ramos Burkitt's lymphoma B cells in consistent with the intracellular ROS content which increases by 20% as early as 0.5 hour and 385% at 6 hours, and the induction of Hsp70 can be blocked by antioxidants N-acetylcysteine (NAC) and Tiron pretreatment. Elesclomol increases the number of early and late apoptotic cells with 3.7- and 11-fold through the induction of oxidative stress, which can be completely blocked by NAC, while having little effect on normal cells. [1] Elesclomol significantly inhibits the cell viability of SK-MEL-5, MCF-7, and HL-60 with IC50 of 110 nM, 24 nM and 9 nM, respectively. [2] Elesclomol induces copper-dependent ROS generation and cytoxicity in yeast. Instead of working through a specific cellular protein target, Elesclomol interacts with the electron transport chain (ETC), a biologically coherent set of processes occurring in the mitochondrion, to generate high levels of ROS within the organelle and consequently cell death. [3]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
NOS-1 cell MmnMS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NVzDd4E1UW6qaXLpeIlwdiCxZjDoeY1idiCQT2OtNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCB|Lk[2[U0xPSEQvF2= MV;TRW5ITVJ?
CAL-51 cell MX;Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M2\kcmlvcGmkaYTpc44hd2ZiaIXtZY4hS0GOLUWxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4yOjZibl2= NXr2OZpuW0GQR1XS
ABC-1 cell NVHubW1zT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= Mn;ZTY5pcWKrdHnvckBw\iCqdX3hckBCSkNvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuN|Y2KG6P M{\0cnNCVkeHUh?=
A2780 cell Ml7oS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MYDJcohq[mm2aX;uJI9nKGi3bXHuJGEzPzhyIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD61PVQhdk1? MXrTRW5ITVJ?
ES1 cell MoDZS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MXnJcohq[mm2aX;uJI9nKGi3bXHuJGVUOSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwN{S5JI5O NHjhOppUSU6JRWK=
HUTU-80 cell NYTyTXdTT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NV6xOYtOUW6qaXLpeIlwdiCxZjDoeY1idiCKVWTVMVgxKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC55OUGgcm0> MknEV2FPT0WU
NCI-H292 cell MUTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M2nZ[2lvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLViyPVIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjh6NjDuUS=> MUDTRW5ITVJ?
NB69 cell NEHCeJdIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M2jOWWlvcGmkaYTpc44hd2ZiaIXtZY4hVkJ4OTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuNlIhdk1? NFP0bmFUSU6JRWK=
ES8 cell M{jSfmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M3:wSWlvcGmkaYTpc44hd2ZiaIXtZY4hTVN6IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MT6zNkBvVQ>? MnuxV2FPT0WU
BCPAP cell M3TkXWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NW\hbWlrUW6qaXLpeIlwdiCxZjDoeY1idiCEQ2DBVEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvOzRibl2= NV\OXI1kW0GQR1XS
T-24 cell NH3ybpBIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NH\pSZdKdmirYnn0bY9vKG:oIHj1cYFvKFRvMkSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlU2KG6P MnXPV2FPT0WU
EW-16 cell NWH3fFI2T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MXvJcohq[mm2aX;uJI9nKGi3bXHuJGVYNTF4IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MT62NUBvVQ>? NIi4PZhUSU6JRWK=
OVCAR-5 cell M4HabWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MnLOTY5pcWKrdHnvckBw\iCqdX3hckBQXkODUj21JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU45OyCwTR?= NXf0RnNXW0GQR1XS
SF126 cell M1fVPWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M3i0SWlvcGmkaYTpc44hd2ZiaIXtZY4hW0ZzMk[gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlk2KG6P MUjTRW5ITVJ?
KP-4 cell MXvHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NXLNWpkyUW6qaXLpeIlwdiCxZjDoeY1idiCNUD20JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk4yPyCwTR?= M3LUbnNCVkeHUh?=
GAMG cell NY[wR2tkT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NIDZNlhKdmirYnn0bY9vKG:oIHj1cYFvKEeDTVegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlUyKG6P NG\lOFNUSU6JRWK=
HOS cell NFzCNlRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M{D5TmlvcGmkaYTpc44hd2ZiaIXtZY4hUE:VIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mj61N{BvVQ>? NYPSWG5bW0GQR1XS
CHL-1 cell Mkf2S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NWfqZ2s2UW6qaXLpeIlwdiCxZjDoeY1idiCFSFytNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvQDFibl2= M1vBO3NCVkeHUh?=
AGS cell MXjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NW\wZVI4UW6qaXLpeIlwdiCxZjDoeY1idiCDR2OgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlg3KG6P MlnNV2FPT0WU
MDA-MB-157 cell Mn30S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MYnJcohq[mm2aX;uJI9nKGi3bXHuJG1FSS2PQj2xOVch[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zNjl{IH7N NWLHXHZFW0GQR1XS
HSC-3 cell NWCyVHlJT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MX\Jcohq[mm2aX;uJI9nKGi3bXHuJGhUSy1|IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mz6wNkBvVQ>? NFL6e2hUSU6JRWK=
CAL-72 cell NYnYNW9nT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NXSx[GFCUW6qaXLpeIlwdiCxZjDoeY1idiCFQVytO|Ih[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{NjB{IH7N MV\TRW5ITVJ?
NBsusSR cell M{WxPWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NYLSXpZ5UW6qaXLpeIlwdiCxZjDoeY1idiCQQoP1d3NTKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oy5zMzDuUS=> MYPTRW5ITVJ?
ES7 cell NGSwU5dIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MlnLTY5pcWKrdHnvckBw\iCqdX3hckBGWzdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1|LkW5JI5O M{LNcXNCVkeHUh?=
H-EMC-SS cell NWj0PWlnT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MorNTY5pcWKrdHnvckBw\iCqdX3hckBJNUWPQz3TV{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvPjhibl2= NUXxbZExW0GQR1XS
NCI-H1703 cell NUjUWXhzT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NGTuNYxKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INVcxOyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTNwNkigcm0> MVzTRW5ITVJ?
BHT-101 cell NUPlXnB4T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NYTaRnV7UW6qaXLpeIlwdiCxZjDoeY1idiCESGStNVAyKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oy55MjDuUS=> MoLhV2FPT0WU
SK-OV-3 cell NV;NSHo3T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MUTJcohq[mm2aX;uJI9nKGi3bXHuJHNMNU:YLUOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlc2KG6P NYfjdHkyW0GQR1XS
EW-24 cell MlLLS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MmDsTY5pcWKrdHnvckBw\iCqdX3hckBGXy1{NDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUOuPFMhdk1? MlzYV2FPT0WU
PSN1 cell M2O0OGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MXPJcohq[mm2aX;uJI9nKGi3bXHuJHBUVjFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1|Lki0JI5O MU\TRW5ITVJ?
OVCAR-8 cell MVjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NHqzOWJKdmirYnn0bY9vKG:oIHj1cYFvKE:YQ1HSMVgh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{Njl7IH7N MkjqV2FPT0WU
NCI-H1563 cell NVLsZZF{T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M33LNmlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVixOVY{KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PC5zMzDuUS=> NVrWZ4NnW0GQR1XS
SW756 cell NEi1WW5Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= M1HBOGlvcGmkaYTpc44hd2ZiaIXtZY4hW1d5NU[gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20MlE{KG6P NYPXWVU1W0GQR1XS
A375 cell MWHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MUnJcohq[mm2aX;uJI9nKGi3bXHuJGE{PzViY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD12LkG0JI5O NEP3U41USU6JRWK=
Ca9-22 cell MXXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MV;Jcohq[mm2aX;uJI9nKGi3bXHuJGNiQS1{MjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUSuNlUhdk1? MVHTRW5ITVJ?
SW1990 cell NV:xcXF3T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M4DyO2lvcGmkaYTpc44hd2ZiaIXtZY4hW1dzOUmwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OE4{OiCwTR?= NIfFR3RUSU6JRWK=
ES4 cell NFLhSHJIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M37Yc2lvcGmkaYTpc44hd2ZiaIXtZY4hTVN2IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;ND6zPUBvVQ>? MlzhV2FPT0WU
HCE-T cell M1rSV2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MlXiTY5pcWKrdHnvckBw\iCqdX3hckBJS0VvVDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUSuOFUhdk1? MorKV2FPT0WU
MOLT-16 cell NIX1eXFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NGPRe|VKdmirYnn0bY9vKG:oIHj1cYFvKE2RTGStNVYh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF01NjV|IH7N MWHTRW5ITVJ?
HSC-4 cell NUTsVpBFT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MmP2TY5pcWKrdHnvckBw\iCqdX3hckBJW0NvNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUSuPEBvVQ>? MY\TRW5ITVJ?
NCI-SNU-1 cell NX7IUpRHT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M2n3ZWlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLWPOWU0yKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PC56NjDuUS=> MnftV2FPT0WU
EW-11 cell MULHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MVfJcohq[mm2aX;uJI9nKGi3bXHuJGVYNTFzIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;ND65JI5O NFrKTXlUSU6JRWK=
HT-1080 cell NY\lUpc2T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NF3FZ4ZKdmirYnn0bY9vKG:oIHj1cYFvKEiWLUGwPFAh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF01Njl7IH7N MoTWV2FPT0WU
MES-SA/Dx5 cells NVKwTIxzS3m2b4TvfIlkcXS7IHHzd4F6 Mnm4R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWVUNVODL1T4OUBk\WyuczygTWM2OD13IH7N M3HNdlI{QTN5OUix
SW1710 cell NXTsNmExT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M3nndGlvcGmkaYTpc44hd2ZiaIXtZY4hW1dzN{GwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU4yPiCwTR?= MWPTRW5ITVJ?
EW-1 cell NGPHcGlIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NHvrb45KdmirYnn0bY9vKG:oIHj1cYFvKEWZLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlI1KG6P MXzTRW5ITVJ?
BV-173 cell M1;nV2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M4nId2lvcGmkaYTpc44hd2ZiaIXtZY4hSlZvMUezJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU4{QSCwTR?= NV;CPJlwW0GQR1XS
TE-8 cell M364O2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MnrDTY5pcWKrdHnvckBw\iCqdX3hckBVTS16IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;NT60NUBvVQ>? MmHhV2FPT0WU
G-401 cell Mn\hS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M4\6PWlvcGmkaYTpc44hd2ZiaIXtZY4hTy12MEGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlQ{KG6P Ml7pV2FPT0WU
KOSC-2 cell NWjMbWVuT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MY\Jcohq[mm2aX;uJI9nKGi3bXHuJGtQW0NvMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUWuOFUhdk1? Mof4V2FPT0WU
HuCCT1 cell MVfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NXLqTIJDUW6qaXLpeIlwdiCxZjDoeY1idiCKdVPDWFEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF02NjV{IH7N Mn;NV2FPT0WU
FADU cell NHvRblVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M4jYd2lvcGmkaYTpc44hd2ZiaIXtZY4hTkGGVTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUWuOlYhdk1? MWrTRW5ITVJ?
MHH-ES-1 cell M3\qTWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M3zkRWlvcGmkaYTpc44hd2ZiaIXtZY4hVUiKLVXTMVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF02NjZ7IH7N MV\TRW5ITVJ?
ES3 cell M{LpXWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MlPpTY5pcWKrdHnvckBw\iCqdX3hckBGWzNiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD13Lke5JI5O NFjUTIxUSU6JRWK=
OVCAR-4 cell M33UOmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NHn2fYJKdmirYnn0bY9vKG:oIHj1cYFvKE:YQ1HSMVQh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF02Njh5IH7N NIiwV2VUSU6JRWK=
HD-MY-Z cell M4nzbWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MUfJcohq[mm2aX;uJI9nKGi3bXHuJGhFNU2\LWqgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlkyKG6P MoS4V2FPT0WU
human JAR cell NUPwXWhqT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NHrOdWtKdmirYnn0bY9vKG:oIHj1cYFvKEqDUjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUWuPVchdk1? NIrWe5VUSU6JRWK=
A427 cell MoH6S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? Mk\pTY5pcWKrdHnvckBw\iCqdX3hckBCPDJ5IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Nj6wO{BvVQ>? M17hN3NCVkeHUh?=
697 cell NGHJfVhIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NX2zNnl3UW6qaXLpeIlwdiCxZjDoeY1idiB4OUegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME22MlE{KG6P MXrTRW5ITVJ?
OVCAR-3 cell MW\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NVvvbopLUW6qaXLpeIlwdiCxZjDoeY1idiCRVlPBVk0{KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Pi5{IH7N M4PTOXNCVkeHUh?=
human NB14 cell NF3mOXVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M4m1[GlvcGmkaYTpc44hd2ZiaIXtZY4hVkJzNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPU[uOlQhdk1? M1ywfHNCVkeHUh?=
GB-1 cell NVHnRmpzT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MknxTY5pcWKrdHnvckBw\iCqdX3hckBISi1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Nj63NUBvVQ>? MXjTRW5ITVJ?
COR-L105 cell MWLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NWi5XIVxUW6qaXLpeIlwdiCxZjDoeY1idiCFT2KtUFExPSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTZwN{[gcm0> NXW2cZkzW0GQR1XS
647-V cell M4jOcmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MWPJcohq[mm2aX;uJI9nKGi3bXHuJFY1Py2YIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Nj65JI5O NFjuOIpUSU6JRWK=
human K5 cell MV;Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MXPJcohq[mm2aX;uJI9nKGi3bXHuJGs2KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PyCwTR?= NU[ySpl3W0GQR1XS
DMS-273 cell M2C2N2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MWfJcohq[mm2aX;uJI9nKGi3bXHuJGROWy1{N{OgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME23MlA3KG6P NYTKeIZwW0GQR1XS
UM-UC-3 cell MnLUS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M3HWcGlvcGmkaYTpc44hd2ZiaIXtZY4hXU1vVVOtN{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVcvODZibl2= NYXUOZJ2W0GQR1XS
HEL cell M4LhVmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NXToVXcyUW6qaXLpeIlwdiCxZjDoeY1idiCKRVygZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME23MlA5KG6P MYjTRW5ITVJ?
human KU-19-19 cell NFHKRXRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MmjsTY5pcWKrdHnvckBw\iCqdX3hckBMXS1zOT2xPUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVcvODlibl2= MXvTRW5ITVJ?
MC-IXC cell MVjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M17SS2lvcGmkaYTpc44hd2ZiaIXtZY4hVUNvSWjDJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9O{4yPyCwTR?= MmfFV2FPT0WU
human H4 cell MlXIS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NHy2PWNKdmirYnn0bY9vKG:oIHj1cYFvKEh2IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Nz6yOUBvVQ>? M{mxUnNCVkeHUh?=
NUGC-3 cell M{H6fWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MX;Jcohq[mm2aX;uJI9nKGi3bXHuJG5WT0NvMzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUeuN|Mhdk1? MlTTV2FPT0WU
CHP-212 cell M1fyTGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NICz[odKdmirYnn0bY9vKG:oIHj1cYFvKEOKUD2yNVIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF04NjN2IH7N NGTxXXpUSU6JRWK=
human SW982 cell M1zBbGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MYrJcohq[mm2aX;uJI9nKGi3bXHuJHNYQTh{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Nz60OEBvVQ>? MnPaV2FPT0WU
C-33-A cell M4rGXWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M4[2NWlvcGmkaYTpc44hd2ZiaIXtZY4hSy1|Mz3BJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9O{42QCCwTR?= MXXTRW5ITVJ?
PC-3 cell NYfYbG5yT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MXzJcohq[mm2aX;uJI9nKGi3bXHuJHBENTNiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD15Lki5JI5O MnfwV2FPT0WU
COLO-684 cell M2PWdGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NYHCO5VxUW6qaXLpeIlwdiCxZjDoeY1idiCFT1zPMVY5PCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTlwMkGgcm0> Mk\UV2FPT0WU
SNU-387 cell NGWx[5FIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NHK5W4VKdmirYnn0bY9vKG:oIHj1cYFvKFOQVT2zPFch[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF06NjR7IH7N MonwV2FPT0WU
U251 cell MorkS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MVPJcohq[mm2aX;uJI9nKGi3bXHuJHUzPTFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD17Lki2JI5O NHPIfnlUSU6JRWK=
A673 cell M{PFTmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NUXUXlc2UW6qaXLpeIlwdiCxZjDoeY1idiCDNkezJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVEvPiCwTR?= NFjYUoJUSU6JRWK=
human T47D cell MV;Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NGTjUlFKdmirYnn0bY9vKG:oIHj1cYFvKFR2N1SgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xOk44QSCwTR?= M3j0WHNCVkeHUh?=
A549 cell M1r1Xmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NHnjc5NKdmirYnn0bY9vKG:oIHj1cYFvKEF3NEmgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xPU43KG6P MnLIV2FPT0WU
PC-14 cell MVzHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NG\wNG5KdmirYnn0bY9vKG:oIHj1cYFvKFCFLUG0JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NlQvPzNibl2= M17LO3NCVkeHUh?=
A704 cell M4jpOmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MUPJcohq[mm2aX;uJI9nKGi3bXHuJGE4ODRiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{Nz60OUBvVQ>? MVfTRW5ITVJ?
MCF7 cell MljRS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MkHoTY5pcWKrdHnvckBw\iCqdX3hckBOS0Z5IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;M{GuN|Yhdk1? M4TJZXNCVkeHUh?=
PC3 cells MUTGeY5kfGmxbjDhd5NigQ>? MoriTY5pcWKrdHnvckBw\iCSRFuxMY1m\GmjdHXkJGFMXCCyaH;zdIhwenmuYYTpc44h[XRiVHjyN|A5KHKnc3nkeYUhcW5iaIXtZY4hWEN|IHPlcIx{KGK7IFXMTXNCNCCLQ{WwQVAvOTF|IN88US=> MkPuNlE{PDF4N{W=
F-36P cells NFXoOmtRem:uaX\ldoF1cW:wIHHzd4F6 MoflRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCILUO2VEBk\WyuczygTWM2OD1yLkK4JO69VQ>? NHz0SGMzOTN2MU[3OS=>
OCI-AML2 cells NFLr[YxRem:uaX\ldoF1cW:wIHHzd4F6 MorBRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCRQ1mtRW1NOiClZXzsd{whUUN3ME2wMlM2KM7:TR?= MUCyNVM1OTZ5NR?=
K562 cells M1zhNnBzd2yrZnXyZZRqd25iYYPzZZk> MlXaRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCNNU[yJINmdGy|LDDJR|UxRTF6IN88US=> NGfvO4YzOTN2MU[3OS=>

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

体内試験 Although Elesclomol (25-100 mg/kg) as a single agent shows no antitumor activity in nude mouse xenograft models of human breast cancers (MDA435, MCF7 and ZR-75-1), lung cancer (RER) or lymphoma (U937), Elesclomol substantially enhances the efficacy of chemotherapeutic agents such as paclitaxel in these models, both in terms of tumor regression and extended survival of mice. [4]

お薦めの試験操作(参考用のみ)

細胞試験: [1]
+ 展開
  • 細胞株: Hs294T, HSB2, and Ramos
  • 濃度: Dissolved in DMSO at a concentration of 10 mM, final concentrations ~500 nM
  • 反応時間: 18, or 24 hours
  • 実験の流れ: Cells are treated with various concentrations of Elesclomol for 18 or 24 hours. The level of intracellular ROS is monitored using the DCFDA probe, which emits a green fluorescence on oxidation. Cell death is determined by flow cytometry of cells double stained with Annexin V/FITC and propidium iodide (PI) using a Vybrant Apoptosis assay kit.
    (参考用のみ)
動物試験:[4]
+ 展開
  • 動物モデル: Female CD-1 nude mice bearing established MDA435 breast cancer xenograft tumors
  • 製剤: Dissolved in DMSO, and diluted in saline
  • 投薬量: ~100 mg/kg
  • 投与方法: Intravenous injection
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 80 mg/mL (199.75 mM)
Water Insoluble
Ethanol Insoluble
体内 左から(NMPから)右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
1% DMSO+30% polyethylene glycol+1% Tween 80
混合させたのち直ちに使用することを推奨します。
30 mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 400.5
化学式

C19H20N4O2S2

CAS No. 488832-69-5
保管
in solvent
別名 N/A

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (g) = 濃度 (mol/L) x 体積 (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01280786 Unknown status Acute Myeloid Leukemia Synta Pharmaceuticals Corp. January 2011 Phase 1
NCT00888615 Active not recruiting Fallopian Tube Clear Cell Adenocarcinoma|Fallopian Tube Endometrioid Adenocarcinoma|Fallopian Tube Mucinous Adenocarcinoma|Fallopian Tube Serous Adenocarcinoma|Fallopian Tube Transitional Cell Carcinoma|Ovarian Brenner Tumor|Ovarian Clear Cell Adenocarcinoma|Ovarian Endometrioid Adenocarcinoma|Ovarian Mucinous Adenocarcinoma|Ovarian Seromucinous Carcinoma|Ovarian Serous Adenocarcinoma|Ovarian Transitional Cell Tumor|Primary Peritoneal Serous Adenocarcinoma|Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma|Undifferentiated Fallopian Tube Carcinoma|Undifferentiated Ovarian Carcinoma Gynecologic Oncology Group|National Cancer Institute (NCI) December 2010 Phase 2
NCT00827203 Suspended Metastatic Solid Tumors Synta Pharmaceuticals Corp. January 2009 Phase 1
NCT00808418 Completed Prostate Cancer Synta Pharmaceuticals Corp. November 2008 Phase 1
NCT00522834 Terminated Melanoma Synta Pharmaceuticals Corp. August 2007 Phase 3
NCT00087997 Completed Soft Tissue Sarcoma Synta Pharmaceuticals Corp. July 2004 Phase 2

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

HSP (e.g. HSP90)シグナル伝達経路

相関HSP (e.g. HSP90)製品

Tags: Elesclomol (STA-4783)を買う | Elesclomol (STA-4783) ic50 | Elesclomol (STA-4783)供給者 | Elesclomol (STA-4783)を購入する | Elesclomol (STA-4783)費用 | Elesclomol (STA-4783)生産者 | オーダーElesclomol (STA-4783) | Elesclomol (STA-4783)化学構造 | Elesclomol (STA-4783)分子量 | Elesclomol (STA-4783)代理店
×

春節(旧正月)休暇に伴う納期遅延のお知らせ
上海工場が春節休業となるため、輸入が必要な製品の納期が通常より2週間ほど遅れます。
1月25日までにご注文いただきました製品は通常通り出荷させていただきます。1月28日-2月8日にご注文いただいた製品は2月19日以降の出荷となります。ご不便をおかけいたしますが、何卒ご理解くださいますようお願い申し上げます。

×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID